• Je něco špatně v tomto záznamu ?

Výsledky koronární angiografie ve studii ASTEROID
[Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden]

Christie M. Ballantyne, et al.

. 2008 ; 2 (5) : 34-35.

Jazyk čeština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc07521954

Previous studies using quantitative coronary angiography have demonstrated that statin therapy slows the progression of coronary stenoses in proportion to average low-density lipoprotein cholesterol levels during therapy. However, no major statin monotherapy study has demonstrated either halted progression or regression of angiographic disease. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) assessed whether rosuvastatin could regress coronary atherosclerosis by intravascular ultrasound and quantitative coronary angiography. Intravascular ultrasound showed atheroma volume regression in a single coronary artery with <50% angiographic luminal narrowing. METHODS AND RESULTS: ASTEROID treated 507 coronary disease patients with rosuvastatin 40 mg/d for 24 months. Blinded quantitative coronary angiography analyses of percent diameter stenosis and minimum lumen diameter were performed for up to 10 segments of coronary arteries and major branches with >25% diameter stenosis at baseline. For each patient, the mean of all matched lesions at baseline and study end was calculated. There were 292 patients with 613 matched stenoses. Rosuvastatin reduced low-density lipoprotein cholesterol by 53.3% to 61.1+/-20.3 mg/dL and increased high-density lipoprotein cholesterol by 13.8% to 48.3+/-12.4 mg/dL. Mean+/-SD percent diameter stenosis decreased from 37.3+/-8.4% (median, 35.7%; range, 26% to 73%) to 36.0+/-10.1% (median, 34.5%; range, 8% to 74%; P<0.001). Minimum lumen diameter increased from 1.65+/-0.36 mm (median, 1.62 mm; range, 0.56 to 2.65 mm) to 1.68+/-0.38 mm (median, 1.67 mm; range, 0.76 to 2.77 mm; P<0.001). CONCLUSIONS: Rosuvastatin treatment for 24 months to average low-density lipoprotein cholesterol levels well below 70 mg/dL, accompanied by significant increases in high-density lipoprotein cholesterol, produced regression by decreasing percent diameter stenosis and improving minimum lumen diameter as measured by quantitative coronary angiography in coronary disease patients.

Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden

000      
00000naa 2200000 a 4500
001      
bmc07521954
003      
CZ-PrNML
005      
20111210133035.0
008      
090423s2008 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Ballantyne, C. M. $q (Christie Mitchell), $d 1955- $7 nlk20040153184
245    10
$a Výsledky koronární angiografie ve studii ASTEROID / $c Christie M. Ballantyne, et al.
246    11
$a Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden
314    __
$a Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston
520    9_
$a Previous studies using quantitative coronary angiography have demonstrated that statin therapy slows the progression of coronary stenoses in proportion to average low-density lipoprotein cholesterol levels during therapy. However, no major statin monotherapy study has demonstrated either halted progression or regression of angiographic disease. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) assessed whether rosuvastatin could regress coronary atherosclerosis by intravascular ultrasound and quantitative coronary angiography. Intravascular ultrasound showed atheroma volume regression in a single coronary artery with <50% angiographic luminal narrowing. METHODS AND RESULTS: ASTEROID treated 507 coronary disease patients with rosuvastatin 40 mg/d for 24 months. Blinded quantitative coronary angiography analyses of percent diameter stenosis and minimum lumen diameter were performed for up to 10 segments of coronary arteries and major branches with >25% diameter stenosis at baseline. For each patient, the mean of all matched lesions at baseline and study end was calculated. There were 292 patients with 613 matched stenoses. Rosuvastatin reduced low-density lipoprotein cholesterol by 53.3% to 61.1+/-20.3 mg/dL and increased high-density lipoprotein cholesterol by 13.8% to 48.3+/-12.4 mg/dL. Mean+/-SD percent diameter stenosis decreased from 37.3+/-8.4% (median, 35.7%; range, 26% to 73%) to 36.0+/-10.1% (median, 34.5%; range, 8% to 74%; P<0.001). Minimum lumen diameter increased from 1.65+/-0.36 mm (median, 1.62 mm; range, 0.56 to 2.65 mm) to 1.68+/-0.38 mm (median, 1.67 mm; range, 0.76 to 2.77 mm; P<0.001). CONCLUSIONS: Rosuvastatin treatment for 24 months to average low-density lipoprotein cholesterol levels well below 70 mg/dL, accompanied by significant increases in high-density lipoprotein cholesterol, produced regression by decreasing percent diameter stenosis and improving minimum lumen diameter as measured by quantitative coronary angiography in coronary disease patients.
650    _2
$a senioři $7 D000368
650    _2
$a LDL-cholesterol $x krev $7 D008078
650    _2
$a koronární angiografie $x metody $7 D017023
650    _2
$a nemoci koronárních tepen $x farmakoterapie $x ultrasonografie $7 D003324
650    _2
$a koronární stenóza $x diagnóza $x farmakoterapie $7 D023921
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluorbenzeny $x aplikace a dávkování $x farmakologie $7 D005464
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pyrimidiny $x aplikace a dávkování $x farmakologie $7 D011743
650    _2
$a sulfonamidy $x aplikace a dávkování $x farmakologie $7 D013449
650    _2
$a výsledek terapie $7 D016896
650    _2
$a intervenční ultrasonografie $7 D018084
650    _2
$a lidé $7 D006801
773    0_
$w MED00012706 $t Clinical cardiology alert $g Roč. 2, č. 5 (2008), s. 34-35 $x 1213-2586
787    18
$w bmc07521957 $i Recenze v: $t Komentář [k článku Výsledky koronární angiografie ve studii ASTEROID]
910    __
$a ABA008 $b B 2242 $c 407 a $y 9
990    __
$a 20090423080915 $b ABA008
991    __
$a 20090601112122 $b ABA008
999    __
$a ok $b bmc $g 645043 $s 497959
BAS    __
$a 3
BMC    __
$a 2008 $b 2 $c 5 $d 34-35 $i 1213-2586 $m Clinical Cardiology Alert $x MED00012706
LZP    __
$a 2009-15/mkme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...